Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment

The Lancet Neurology

Volumn 8, Issue 5, 2009, Pages 464-474

  Chaudhuri, K Ray ^a,b   Schapira, Anthony HV ^c  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; APOMORPHINE; BENSERAZIDE; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; FLUOXETINE; LEVODOPA; PERGOLIDE; PLACEBO; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE; SAFINAMIDE; SERTRALINE;

ADD ON THERAPY; AKATHISIA; AKINESIA; ANORECTAL DISEASE; ANXIETY DISORDER; APATHY; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTINUOUS INFUSION; DEPRESSION; DISEASE EXACERBATION; DOPAMINERGIC SYSTEM; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; ERECTILE DYSFUNCTION; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; HYPERALGESIA; LIMB MOVEMENT; MUSCLE SPASM; NOCTURIA; NONHUMAN; PAIN; PARKINSON DISEASE; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; REVIEW; SEXUAL DYSFUNCTION; SLEEP DISORDER; TREATMENT RESPONSE; VISUAL IMPAIRMENT;

ANTIPARKINSON AGENTS; BEHAVIORAL SYMPTOMS; BRAIN; DEEP BRAIN STIMULATION; DOPAMINE; DOPAMINE AGENTS; GASTROINTESTINAL DISEASES; HUMANS; PAIN; PARKINSON DISEASE; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SLEEP DISORDERS; UROLOGIC DISEASES; VISUAL PERCEPTION;

EID: 64349083816     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(09)70068-7     Document Type: Review

References (113)

1. Chaudhuri K.R., Healy D., and Schapira A. The non motor symptoms of Parkinson's disease. Diagnosis and management. Lancet Neurol 5 (2006) 235-245
2. The National Institute for Clinical Excellence (NICE). Parkinson's disease diagnosis and management in primary and secondary care. Clinical guideline 35 (June, 2006). http://www.nice.org.uk/nicemedia/pdf/cg035quickrefguide.pdf (accessed March 24, 2009).
3. Shulman L.M., Taback R.L., Rabinstein A.A., and Weiner W.J. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord 8 (2002) 193-197
4. Mitra T, Naidu Y, Martinez-Martin P, et al. The non declaration of non motor symptoms of Parkinson's disease to healthcare professionals. An international survey using the NMSQuest. 6th International Congress on Mental Dysfunctions and other Non-motor Features in Parkinson's disease and Related Disorders. Dresden October, 2008. Park Related Disorders P0II: 161.
5. Global Parkinson's Disease Survey Steering Committee. Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov Disord 17 (2002) 60-107
6. Schrag A., Jahanshahi M., and Quinn N. What contributes to quality of life in patients with Parkinson's disease?. J Neurol Neurosurg Psychiatry 69 (2000) 308-312
7. Findley L., Aujla M., Bain P.G., et al. Direct economic impact of Parkinson's disease: a research survey in the United Kingdom. Mov Disord 18 (2003) 1139-1145
8. Hagell P., Nordling S., Reimer J., Grabowski M., and Persson U. Resource use and costs in a Swedish cohort of patients with Parkinson's disease. Mov Disord 17 (2002) 1213-1220
9. Chaudhuri K.R., and Martinez-Martin P. Quantitation of non-motor symptoms in Parkinson's disease. Eur J Neurol 15 (2008) 2-7
10. Fox S.H., Brotchie J.M., and Lang A.E. Non-dopaminergic treatment in development for Parkinson's disease. Lancet Neurol 7 (2008) 927-938
11. Chaudhuri K.R., Martinez-Martin P., Schapira A., et al. An international multicentre pilot study of the first comprehensive self-completed non-motor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord 21 (2006) 916-923
12. Naidu Y., and Chaudhuri K.R. Early Parkinson's disease and non motor issues. J Neurol 255 (2008) 33-38
13. O'Sullivan S.S., Williams D.R., Gallagher D.A., Massey L.A., Silveira-Moriyama L., and Lees A.J. Non motor symptoms as presenting complaints in Parkinson's disease: a clinicopathological study. Mov Disord 23 (2008) 101-106
14. Braak H., Del Tredici K., Rüb U., de Vos R., Steur E.J., and Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24 (2003) 197-210
15. Wolters E., and Braak J. Parkinson's disease: premotor clinico-pathological correlations. Neural Trans 70 (2006) 309-319
16. Politis M., Piccini P., Pavese N., and Brooks D.J. Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: an in vivo 11C-raclopride study. Exp Neurol 214 (2008) 112-116
17. Aarsland D., Larsen J.P., Lim N.G., et al. Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 67 (1999) 492-496
18. Burn D.J. Beyond the iron mask; towards better recognition and treatment of depression associated with Parkinson's disease. Mov Disord 17 (2002) 445-454
19. Aarsland D., Andersen K., Larsen J.P., Lolk A., and Kragh-Sørensen P. Prevalence and characteristics of dementia in Parkinson disease. Arch Neurol 60 (2003) 387-392
20. Remy P., Doder M., Lees A., et al. Depression in Parkinson's disease. Loss of dopamine and noradrenaline innervations in the limbic system. Brain 128 (2005) 1314-1322
21. Corrigan M.H., Denahan A.Q., Wright C.E., Ragual R.J., and Evans D.L. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 11 (2000) 58-65
22. Goldberg J., Burdick K.E., and Endick C.J. Prelimimary randomised placebo controlled trial of pramipexole added to mood stabilisers for treatment resistant bipolar depression. Am J Psychiatry 161 (2004) 564-566
23. Rektorova I., Rektor I., Bares M., et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 10 (2003) 399-406
24. Barone P., Scarzella L., Marconi R., et al. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease. A national multicenter parallel group randomized study. J Neurol 253 (2006) 601-607
25. Reichmann H., Brecht M.H., Koster J., et al. Pramipexole in routine clinical practice: a prospective observational trial in Parkinson's disease. CNS Drugs 17 (2003) 965-973
26. Pahwa R., Stacy M.A., Factor S.A., et al., on behalf of the EASE-PD adjunct study investigators. Ropinirole 24- hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 68 (2007) 1108-1115
27. Boehringer Ingelheim Pharmaceuticals. Pramipexole versus placebo in Parkinson's disease (PD) patients with depressive symptoms. NCT00297778. http://clinicaltrials.gov/ct2/show/NCT00297778 (accessed March 25, 2009).
28. Learned-Coughlin S.M., Bergstrom M., Savitcheva I., Ascher J., Schmith V.D., and Langstrom B. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry 54 (2003) 800-805
29. Schmitt J.A., Ramaekers J.G., Kruizinga M.J., van Boxtel M.P., Vuurman E.F., and Riedel W.J. Additional dopamine reuptake inhibition attenuates vigilance impairment induced by serotonin reuptake inhibition in man. J Psychopharmacol 16 (2002) 207-214
30. Lemke M.R., Brecht H.M., Koester J., et al. Anhedonia, depression and motor functioning in Parkinson's disease during treatment with pramipexole. J Neuropsychiatry Clin Neurosci 17 (2005) 214-220
31. Richard I.H., Schiffer R.B., and Kurlan R. Anxiety and Parkinson's disease. J Neuropsychatry Clin Neurosci 8 (1996) 383-392
32. Kulisevsky J., Pascual-Sedano B., Barbanoj M., et al. Acute effects of immediate and controlled release levodopa on mood in Parkinson's disease: a double blind study. Mov Disord 22 (2006) 62-67
33. Witt K., Daniels C., Reiff J., Krack P., et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study. Lancet Neurol 7 (2008) 605-614
34. Wijtas T., Kaphan E., Regis G., et al. Effects of chronic subthalamic stimulation on non motor fluctuations in Parkinson's disease. Mov Disord 22 (2007) 1729-1734
35. Czernecki V., Schupbach M., Yaici S., et al. Apathy following subthalamic stimulation in Parkinson's disease: a dopamine responsive syndrome. Mov Disord 23 (2008) 964-969
36. Marin R.S., Fogel B.S., Hawkin J., et al. Apathy: a treatable syndrome. J Neuropsychiatry Clin Neurosci 7 (1995) 23-30
37. Czernecki V., Pillon B., Houeto J.L., et al. Motivation, reward and Parkinson's disease: influence of dopa therapy. Neuropsychologia 40 (2002) 2257-2267
38. Dubois B., and Pillon B. Cognitive deficits in Parkinson's disease. J Neurology 244 (1997) 2-8
39. Uc E., Rizzo M., Anderson S., Qian S., Rodnitzky R., and Dawson J. Visual dysfunction in Parkinson disease without dementia. Neurology 65 (2005) 1907-1913
40. Williams-Gray C., Foltynie T., Brayne C., Robbins T., and Barker R. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 130 (2007) 1787-1798
41. Emre M. What causes mental dysfunction in Parkinson's disease?. Mov Disord 18 (2003) S63-S71
42. Lewis S., Dove A., Robbins T., Barker R., and Owen A. Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry. J Neurosci 23 (2003) 6351-6356
43. Rinne J., Portin R., Ruottinen H., et al. Cognitive impairment and the brain dopaminergic system in Parkinson disease-[F-18]fluorodopa positron emission tomographic study. Arch Neurol 57 (2000) 470-475
44. Cools R., Stefanova E., Barker R., Robbins T., and Owen A. Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET. Brain 125 (2002) 584-594
45. Mattay V., Tessitore A., Callicott J., et al. Dopaminergic modulation of cortical function in patients with Parkinson's disease. Ann Neurol 51 (2002) 156-164
46. Anand R., Onofrj M., Schapira A.H., et al. Safinamide potentiates the effects of DA-agonists in early stage Parkinson's disease (PD) patients. Mov Disord 22 suppl 16 (2007) 797
47. Ng K.Y., Chase T.N., Colburn R.W., et al. Dopamine stimulation induced release from central neurons. Science 1172 (1971) 487-489
48. Rye D.B., and Jankovic J. Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD. Neurology 58 (2002) 341-346
49. Saper C., Chou T.C., and Scammell T.E. The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci 24 (2001) 726-731
50. Dhawan V., Healy D.G., Pal S., and Chaudhuri K.R. Sleep-related problems of Parkinson's disease. Age Ageing 35 (2006) 220-228
51. Lees A.J., Blackburn N.A., and Campbell V.L. The night time problems of Parkinson's disease. Clin Neuropharmacol 11 (1988) 512-519
52. Leeman A.L., O'Neill C.J., Nicholson P.W., et al. Parkinson's disease in the elderly: response to and optimal spacing of night time dosing with levodopa. Br J Clin Pharmacol 24 (1987) 637-643
53. Stocchi F., Barbato L., Nordera G., et al. Sleep disorders in Parkinson's disease. J Neurol 245 (1998) S15-S18
54. Van Den Kerchove M., Jacquy J., Gonce M., et al. Sustained-release levodopa in parkinsonian patients with nocturnal disabilities. Acta Neurol Belg 93 (1993) 32-39
55. Chaudhuri K.R., Bhattacharya K., Agapito C., et al. The use of cabergoline in nocturnal parkinsonian disabilities causing sleep disruption: a parallel study with controlled-release levodopa. Eur J Neurol 6 (1999) S11-S15
56. Poewe W., Rascol O., Quinn N., et al., on behalf of the Sp515 investigators. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double blind, double dummy, randomised controlled trial. Lancet Neurol 6 (2007) 513-520
57. Muzerengi S., Lewis H., and Chaudhuri K.R. Restless legs syndrome: a review of diagnosis and management. Int J Sleep Disord 1 (2006) 34-46
58. Schapira A.H. Restless legs syndrome: an update on treatment options. Drugs 64 (2004) 149-158
59. Garcia-Borreguero D., Odin P., and Serrano C. Restless legs syndrome and PD: a review of the evidence for a possible association. Neurology 61 (2003) 49-55
60. Ondo W.G., Vuong K.D., and Jankovic J. Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol 59 (2002) 421-424
61. Comella C.L., and Goetz C.G. Akathisia in Parkinson's disease. Mov Disord 9 (1994) 545-549
62. Reuter I., Ellis C.M., and Chaudhuri K.R. Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome. Acta Neurol Scand 100 (1999) 163-167
63. Högl B., Rothdach A., Wetter T.C., and Trenkwalder C. The effect of cabergoline on sleep, periodic leg movements in sleep, and early morning motor function in patients with Parkinson's disease. Neuropsychopharmacology 28 (2003) 1866-1870
64. Schenck C.H., Bundlie S.R., Ettinger M.G., and Mahowald M.W. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. Sleep 9 (1986) 293-308
65. Schenck C.H., and Mahowald M.W. REM sleep behavior disorder: clinical, developmental, and neuroscience perspectives 16 years after its formal identification in SLEEP. Sleep 25 (2002) 120-138
66. Boeve B.F., Silber M.H., Saper B., et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain 130 (2007) 2770-2788
67. Tan A., Salgado M., and Fahn S. Rapid eye movement sleep behaviour disorder preceding Parkinson's disease with therapeutic response to levodopa. Mov Disord 11 (1996) 214-216
68. Iranzo A., Molinuevo J.L., Santamaría J., et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol 5 (2006) 572-577
69. Postuma R.B., Gagnon J.F., Vendette M., Fantini M.L., Massicotte-Marquez J., and Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behaviour disorder. Neurology (2008) 10.1212/01.wnl.0000340980.19702.6e published online December 24.
70. Fantini M.L., Gagnon J.-F., Filipini D., et al. The effects of paramipexole in REM sleep behavior disorder. Neurology 61 (2003) 1418-1420
71. Rye D. The pathophysiology of REM sleep behaviour disorder. Sleep 21 (1998) 446-449
72. Yamouchi K., Takehisa M., Tsuno M., et al. Levodopa improved rapid eye movement sleep behaviour disorder with diffuse Lewy body diease. Gen Hosp Psychiatry 25 (2003) 136-144
73. Yoshimura N., Sass M., Yoshida O., and Takori S. Dopamine D1 receptor-mediated inhibition of micturition reflex by central dopamine from the substantia nigra. Neurourol Urodyn 11 (1992) 535-545
74. Seki S., Igawa Y., Kaidoh K., Ishizuka O., Nishizawa O., and Andersson K.E. Role of dopamine D1 and D1 receptors in the micturition reflex in conscious rats. Neurourology Urodyn 20 (2001) 105-113
75. Uchiyama T., Sakakibara R., Hattori T., and Yamanishi T. Short-term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing-off phenomenon. Mov Disord 18 (2003) 573-578
76. Christmas T., Kempster P., Chapple C., et al. Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet 2 (1988) 1451-1453
77. Yoshimura N., Mizuta E., Yoshida O., and Kuno S. Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys. J Pharmacol Exp Ther 286 (1998) 228-233
78. Kuno S., Mizuta E., Yamasaki S., and Araki I. Effects of pergolide on nocturia in Parkinson's disease: three female cases selected from over 400 patients. Parkinsonism Relat Disord 10 (2004) 181-187
79. Winge K., Werdelin L.M., Nielsen K.K., and Stimpel H. Effects of dopaminergic treatment on bladder function in Parkinson's disease. Neurourol Urodyn 23 (2004) 689-696
80. Seif C., Herzog J., van der Horst C., et al. Effect of subthalamic deep brain stimulation on the function of the urinary bladder. Ann Neurol 55 (2004) 118-120
81. Martinez-Martin P., Schapira A., Stocchi F., et al. Prevalence of non motor symptoms in Parkinson's disease in an international setting; study using non-motor symptoms questionnaire in 545 patients. Mov Disord 22 (2007) 1623-1629
82. Giladi N., Mair K.J., Badenhorst F., Dank N., and Boroojerdi B. Effects of rotigotine transdermal patch on early morning motor function, sleep quality and daytime sleepiness in patients with idiopathic disease. Results of a multicenter, multinational trial (abstract). Eur J Neurol 13 (2006) 74
83. Metta V., Naidu Y., Muzerengi S., et al. The beneficial effect of rotigotine transdermal patch on nocturia in Parkinson's disease. 6th Intenational Congress on Mental Dysfunctions and Other Non Motor Features in Parkinson's Disease. Dresden, October, 2008. Park Relat Disord (2008) abstract P01:51.
84. Bronner G., Royter V., Korczyn A., et al. Sexual dysfunction in Parkinson's disease. J Sex Marital Ther 30 (2004) 95-105
85. Wolters E.C., and Braak H. Parkinson's disease: premotor premotor clinicopathological correlations. J Neural Trans 70 (2006) 309-319
86. Robinson B.W., and Mishkin M. Penile erection evoked from forebrain structures in Macaca mulatta. Arch Neurol 19 (1968) 184-198
87. Temel Y., Van Lankveld J.J., Boon P., et al. Deep brain stimulation of the thalamus can influence penile erection. Int J Impot Res 16 (2004) 91-94
88. Moller J.C., Eggert K.M., Unger M., Odin P., Chaudhuri K.R., and Oertel W. Clinical risk benefit assessment of dopamine agonists. Eur J Neurol 15 (2008) 15-23
89. Klos K.J., Bower J.H., Josephs K.A., Matsumoto J.Y., and Ahlskog J.E. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Park Relat Disord 11 (2005) 381-386
90. O'Sullivan J.D., and Hughes A.J. Apomorphine induced penile erections in Parkinson's disease. Mov Disord 13 (1998) 536-539
91. Dula E., Bukofzer S., Perdok R., et al. Double blind crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur Urol 39 (2001) 558-564
92. Singharam C., Ashraf W., Gaummitz E.A., et al. Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation. Lancet 346 (1995) 861-864
93. Edwards L.L., Quigley E., Harned R.K., Hofman, Ruth, and Pfeiffer R.F. Defecatory function in Parkinson's disease: response to apomorphine. Ann Neurol 33 (1992) 490-493
94. Honig H, Antonini A, Martinez-Martin P, et al. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicentre study of effects on non-motor symptoms and quality of life. Mov Disord (in press).
95. Chudler E.H., and Dong W.K. The role of the basal ganglia in nociception and pain. Pain 60 (1995) 3-38
96. Shyu B.C., Kititsy-Roy J.A., and Morrow T.J. Neurophysiological, pharmacological and behavioural evidence for medial thalamic mediation of cocaine induced dopaminergic analgesia. Brain Res 522 (1992) 216-223
97. Nègre-Pagès L., Regragui W., Bouhassira D., et al., for the DoPaMiP Study Group. Chronic pain in Parkinson's disease: the cross-sectional French DoPaMiP survey. Mov Disord 23 (2008) 1361-1369
98. Defazio G., Berardelli A., Fabbrini G., et al. Pain as a non motor symptom of Parkinson disease: evidence from a case-control study. Arch Neurol 65 (2008) 1191-1194
99. Quinn N.P., Koller W.C., Lang A.E., and Marsden C.D. Painful Parkinson's disease. Lancet 1 (1986) 1366-1369
100. Brefel-Courbon C., Payoux P., Thalamas C., et al. Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. Mov Disord 20 (2005) 1557-1563
101. Schestatsky P., Kumru H., Valls-Sole J., et al. Neurophysiologic study of central pain in patients with parkinson disease. Neurology 69 (2007) 2162-2169
102. Djaldetti R., Shifrin A., Rogowski Z., Sprecher E., Melamed E., and Yarnitsky D. Quantitative measurement of pain sensation in patients with Parkinson disease. Neurology 62 (2004) 2171-2175
103. Loher T.J., Burgander J.-M., Weber S., Sommerhalder R., and Krauss J.K. Effect of chronic pallidal deep brain stimulation off period dystonia and sensory symptoms in advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 73 (2002) 395-399
104. Büttner T., Kuhn W., Müller T., et al. Distorted color discrimination in 'de novo' parkinsonian patients. Neurology 45 (1995) 386-387
105. Postuma R.B., Lang A.E., Massicotte-Marquez J., and Montplaisir J. Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology 66 (2006) 845-851
106. Nguyen-Legros J. Functional neuroarchitecture of the retina: Hypothesis on the dysfunction of retinal dopaminergic circuitry in Parkinson's disease. Surg Radiol Anat 10 (1988) 137-144
107. Harnois C., and Di Paolo T. Decreased dopamine in the retinas of patients with Parkinson's disease. Invest Ophtalmol Visual Sci 31 (1990) 2473-2475
108. Devos D., Tir M., Maurage C.A., et al. ERG and anatomical abnormalities suggesting retinopathy in dementia with Lewy bodies. Neurology 65 (2005) 1107-1110
109. Willis G.L. Parkinson's disease as a neuroendocrine disorder of circadian function: dopamine-melatonin imbalance and the visual system in the genesis and progression of the degenerative process. Rev Neurosci 19 (2008) 245-316
110. Wink B., and Harris J. A model of the Parkinsonian visual system: support for the dark adaptation hypothesis. Vision Res 40 (2000) 1937-1946
111. Witjas T., Kaphan E., and Azulay J.P. Non-motor fluctuations in Parkinson's disease. Rev Neurol 163 (2007) 846-850
112. Witjas T., Kaphan E., Azulay J.P., et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 59 (2002) 408-413
113. Stacy M., Bowron A., Guttman M., et al. Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord 20 (2005) 726-733